Prosecution Insights
Last updated: May 29, 2026
Application No. 18/005,519

PHOTOREDOX PROTEIN MODIFICATION

Non-Final OA §112
Filed
Jan 13, 2023
Priority
Jul 16, 2020 — GB 2010989.8 +1 more
Examiner
JARRELL, NOBLE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Rosalind Franklin Institute
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
830 granted / 1021 resolved
+21.3% vs TC avg
Moderate +9% lift
Without
With
+9.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
59 currently pending
Career history
1077
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
22.3%
-17.7% vs TC avg
§102
18.6%
-21.4% vs TC avg
§112
32.6%
-7.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1021 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of group I and a compound of formula (II) in the reply filed on 2026 January 20 is acknowledged. Due to no prior art against the method of claim 1 and a compound of formula (II), a search of claim 1 is extended to a compound of formula (III). Claims 1-9, 11, 12, 14-16, 18-24, and 28 are pending. Claims 1-6, 8, 9, 11, 12, 14, 15, 16, 18, and 19 are examined on the merits. Claims 7, 20-24, and 28 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 2026 January 20. Information Disclosure Statement The information disclosure statement (IDS) submitted on 2023 May 15 was submitted in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-6, 8, 9, 11, 12, 14, 15, 16, 18, and 19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1-6, 8, 9, 11, 12, 14, 15, 16, 18, and 19 are unclear for the following reasons. The structural metes and bounds of singly occupied molecular orbital, SOMO, acceptor residue. Claim 1 only specifies that it comprises an alkene group. What other functional groups are present in the SOMO acceptor residue? In formula (III), the boron ring heteroatom has a formal charge of negative one because it is attached to four groups. What is the corresponding cation that neutralizes this anion? What are the structural metes and bounds of variable R? Claim 1 does not provide any guidance to the functional groups that are permitted to be present in this variable. In claim 19, what group is attached to functionalized-B-CH2R so it can react with a catechol of formula (IIB)? Boron needs three groups to attached to be neutral. Claim 2, 4-6, and 9 recite various groups for variable R. There is insufficient antecedent basis for this limitation in the claim because claim 1 does not recite clear metes and bounds with respect to variable R. Claim 8 and 11 each recites a possibility for the SOMO acceptor residue. There is insufficient antecedent basis for this limitation in these claims because claim 1 does not recite clear metes and bounds with respect to this group. Regarding claim 2, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. Is the linker limited to any linker group or the group L1? The usage of the word “preferably” is interpreted “such as”. See MPEP § 2173.05(d). Regarding claim 12, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. Is group A limited to the first four groups, the second three groups, or only 2-pyridinyl. See MPEP § 2173.05(d). Regarding claim 15, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. Is the source of Fe(II) limited to the five first sources or the last one, FeSO4•H2O? See MPEP § 2173.05(d). Regarding claim 16, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. Is the photocatalyst limited to a Ru(II) or Ir(II) based catalyst, a Ru(II) catalyst, or Ru(bpy)3Cl2 or Ru(bpm)3Cl2? See MPEP § 2173.05(d). Regarding claim 18, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. What wavelength range do applicants intend for the light radiation: 300 to 600 nm; 400 to 500 nm; or 430 to 470 nm? See MPEP § 2173.05(d). Conclusion Claims 1-6, 8, 9, 11, 12, 14, 15, 16, 18, and 19 are not allowed. The following is a statement of reasons for the indication of allowable subject matter: SUN (US 20250257095, published 2025 August 14) describes example 1 (pages 20-21, paragraphs [0121]-[0123]. This does not anticipate or render obvious a process of claim 1 because an unsaturated cyclic group is not attached to a sulfonyl group and the reference was published 2025 August 14, which is after the effective filing date of 2020 July 16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 9:00 AM to 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NOBLE E JARRELL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Jan 13, 2023
Application Filed
May 11, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12630589
COMPOUNDS FOR USE IN VIRAL INFECTIONS
3y 8m to grant Granted May 19, 2026
Patent 12624080
Multi-receptor (GLP-1 receptor, GIP receptor, and Gcg receptor) agonist protein
3y 11m to grant Granted May 12, 2026
Patent 12595235
PROCESS FOR PRODUCING 4,5-DIHYDRO-1H-PYRAZOLES AND INTERMEDIATES
3y 6m to grant Granted Apr 07, 2026
Patent 12595265
INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE
2y 11m to grant Granted Apr 07, 2026
Patent 12588410
ORGANIC ELECTROLUMINESCENT MATERIAL AND METHOD PREPARING THE SAME
3y 3m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
90%
With Interview (+9.0%)
2y 11m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1021 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month